Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

This study has been terminated.
Sponsor:
Collaborator:
Eudax S.r.l.
Information provided by (Responsible Party):
Philogen S.p.A.
ClinicalTrials.gov Identifier:
NCT01055522
First received: January 22, 2010
Last updated: February 24, 2014
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2014
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
No publications provided by Philogen S.p.A.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):